Alembic Pharmaceuticals received an FDA warning letter after failing to obtain informed consent from patients for a clinical study, according to the company’s notice. The FDA cited a consent lapse that prompted the warning, continuing a pattern of enforcement that targets fundamental trial ethics and documentation. The warning is notable because informed-consent handling is a core requirement for global trial integrity, affecting data acceptability across jurisdictions. For generics and contract-driven development programs, even process issues can delay study execution and complicate future submissions. Industry compliance teams are likely to use the case to tighten consent workflow controls, documentation practices, and oversight for participating sites.